Prolonged Anaphylaxis to Pfizer Coronavirus Disease 2019 Vaccine: A Case Report and Mechanism of Action

BACKGROUND: In response to the devastating effects of the coronavirus disease 2019 pandemic, several vaccine prototypes have been developed, with the Pfizer/BioNTech (BNT162b2) platform being the first to receive emergency use authorization. Although taken to market on an unprecedented timeline, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Frank, Ashleigh, Radparvar, Sara, Manasia, Anthony, Bassily-Marcus, Adel, Kohli-Seth, Roopa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021358/
https://www.ncbi.nlm.nih.gov/pubmed/33834172
http://dx.doi.org/10.1097/CCE.0000000000000397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021358/
https://www.ncbi.nlm.nih.gov/pubmed/33834172
http://dx.doi.org/10.1097/CCE.0000000000000397

Ejemplares similares